Literature DB >> 10881890

Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women.

K A Chan1, S E Andrade, M Boles, D S Buist, G A Chase, J G Donahue, M J Goodman, J H Gurwitz, A Z LaCroix, R Platt.   

Abstract

BACKGROUND: Inhibitors of hydroxymethylglutaryl-coenzyme A reductase (statins) increase new bone formation in rodents and in human cells in vitro. Statin use is associated with increased bone mineral density of the femoral neck. We undertook a population-based case-control study at six health-maintenance organisations in the USA to investigate further the relation between statin use and fracture risk among older women.
METHODS: We investigated women aged 60 years or older. Exposure, outcome, and confounder information was obtained from automated claims and pharmacy data from October, 1994, to September, 1997. Cases had an incident diagnosis of non-pathological fracture of the hip, humerus, distal tibia, wrist, or vertebrae between October, 1996, and September, 1997. Controls had no fracture during this period. We excluded women with records of dispensing of drugs to treat osteoporosis.
FINDINGS: There were 928 cases and 2747 controls. Compared with women who had no record of statin dispensing during the previous 2 years, women with 13 or more statin dispensings during this period had a decreased risk of non-pathological fracture (odds ratio 0.48 [95% CI 0.27-0.83]) after adjustment for age, number of hospital admissions during the previous year, chronic disease score, and use of non-statin lipid-lowering drugs. No association was found between fracture risk and fewer than 13 dispensings of statins or between fracture risk and use of non-statin lipid-lowering drugs.
INTERPRETATION: Statins seem to be protective against non-pathological fracture among older women. These findings are compatible with the hypothesis that statins increase bone mineral density in human beings and thereby decrease the risk of osteoporotic fractures.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10881890     DOI: 10.1016/S0140-6736(00)02400-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  76 in total

Review 1.  Statins and bones.

Authors:  M H Moghadasian; J J Frohlich
Journal:  CMAJ       Date:  2001-03-20       Impact factor: 8.262

2.  Lipid-lowering agents and the risk of hip fracture in a Medicaid population.

Authors:  W A Ray; J R Daugherty; M R Griffin
Journal:  Inj Prev       Date:  2002-12       Impact factor: 2.399

Review 3.  Isoprenoids as mediators of the biological effects of statins.

Authors:  James K Liao
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 4.  HMG CoA reductase inhibitors and the skeleton: a comprehensive review.

Authors:  D C Bauer
Journal:  Osteoporos Int       Date:  2003-05-08       Impact factor: 4.507

5.  Statin therapy: having the good without the bad.

Authors:  James K Liao
Journal:  Hypertension       Date:  2004-06       Impact factor: 10.190

6.  Hypercholesterolemia promotes an osteoporotic phenotype.

Authors:  Kristine Pelton; Jaclynn Krieder; Danese Joiner; Michael R Freeman; Steven A Goldstein; Keith R Solomon
Journal:  Am J Pathol       Date:  2012-07-04       Impact factor: 4.307

7.  Statin use and risk of fracture: a meta-analysis.

Authors:  Shaolin Jin; Jianping Jiang; Pengcheng Bai; Mei Zhang; Xujun Tong; Hui Wang; Youqun Lu
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 8.  Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis.

Authors:  Christos Hatzigeorgiou; Jeffrey L Jackson
Journal:  Osteoporos Int       Date:  2005-03-03       Impact factor: 4.507

9.  Effects of simvastatin on bone mineral density and remodeling parameters in postmenopausal osteopenic subjects: 1-year follow-up study.

Authors:  Canan Tikiz; Hakan Tikiz; Fatma Taneli; Gül Gümüşer; Ciğdem Tüzün
Journal:  Clin Rheumatol       Date:  2005-03-02       Impact factor: 2.980

Review 10.  Statin therapy in the elderly: does it make good clinical and economic sense?

Authors:  Moira M B Mungall; Allan Gaw; James Shepherd
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.